1. Home
  2. AGIO vs ATEC Comparison

AGIO vs ATEC Comparison

Compare AGIO & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • ATEC
  • Stock Information
  • Founded
  • AGIO 2007
  • ATEC 1990
  • Country
  • AGIO United States
  • ATEC United States
  • Employees
  • AGIO N/A
  • ATEC N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • ATEC Medical/Dental Instruments
  • Sector
  • AGIO Health Care
  • ATEC Health Care
  • Exchange
  • AGIO Nasdaq
  • ATEC Nasdaq
  • Market Cap
  • AGIO 1.4B
  • ATEC 1.4B
  • IPO Year
  • AGIO 2013
  • ATEC 2006
  • Fundamental
  • Price
  • AGIO $27.66
  • ATEC $10.56
  • Analyst Decision
  • AGIO Buy
  • ATEC Strong Buy
  • Analyst Count
  • AGIO 8
  • ATEC 10
  • Target Price
  • AGIO $56.57
  • ATEC $17.60
  • AVG Volume (30 Days)
  • AGIO 745.1K
  • ATEC 2.2M
  • Earning Date
  • AGIO 05-01-2025
  • ATEC 05-01-2025
  • Dividend Yield
  • AGIO N/A
  • ATEC N/A
  • EPS Growth
  • AGIO N/A
  • ATEC N/A
  • EPS
  • AGIO 11.64
  • ATEC N/A
  • Revenue
  • AGIO $36,498,000.00
  • ATEC $611,562,000.00
  • Revenue This Year
  • AGIO $41.13
  • ATEC $22.13
  • Revenue Next Year
  • AGIO $234.96
  • ATEC $18.55
  • P/E Ratio
  • AGIO $2.38
  • ATEC N/A
  • Revenue Growth
  • AGIO 36.07
  • ATEC 26.81
  • 52 Week Low
  • AGIO $23.42
  • ATEC $4.88
  • 52 Week High
  • AGIO $62.58
  • ATEC $13.79
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 44.94
  • ATEC 54.85
  • Support Level
  • AGIO $26.87
  • ATEC $9.80
  • Resistance Level
  • AGIO $28.24
  • ATEC $10.31
  • Average True Range (ATR)
  • AGIO 1.94
  • ATEC 0.70
  • MACD
  • AGIO 0.22
  • ATEC 0.07
  • Stochastic Oscillator
  • AGIO 66.15
  • ATEC 91.15

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About ATEC Alphatec Holdings Inc.

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.

Share on Social Networks: